Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLENO: Safety of Switching to Plegridy in RRMS
NCT03177083Phase 4Completed
- Sponsor
- Biogen
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon beta-1a in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoints: Combined Counts of Adverse Events of Flu-Like Symptoms at 24 weeks, Combined Counts of Adverse Events of Injection Site Reactions at 24 weeks and 1 more. Started Jan 2017; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03177083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177083.